Area of research
Cancer Research · Pathology and Forensic Medicine
Research interest
Research interests include Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, Cancer survivorship and care, and Breast Implant and Reconstruction.
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights
Abstract GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis
Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates
Redlining−associated methylation in breast tumors: the impact of contemporary structural racism on the tumor epigenome
DNA methylation signature of chronic low-grade inflammation and its role in cardio-respiratory diseases
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy
Female erectile tissues and sexual dysfunction after pelvic radiotherapy: A scoping review
Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities
Exosomal Metabolic Signatures Are Associated with Differential Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
Receipt of Guideline-Concordant Care Does Not Explain Breast Cancer Mortality Disparities by Race in Metropolitan Atlanta
Type 2 diabetes, breast cancer specific and overall mortality: Associations by metformin use and modification by race, body mass, and estrogen receptor status
Automatic Breast Cancer Cohort Detection from Social Media for Studying Factors Affecting Patient-Centered Outcomes
Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?
Disadvantaged neighborhoods and racial disparity in breast cancer outcomes: the biological link
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
Time to Radiation After Oncoplastic Reduction
CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy
Massage therapy decreases cancer‐related fatigue: Results from a randomized early phase trial
Comparison of different cell type correction methods for genome-scale epigenetics studies
Depressive symptoms and inflammation are independent risk factors of fatigue in breast cancer survivors
Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
ATRIP Deacetylation by SIRT2 Drives ATR Checkpoint Activation by Promoting Binding to RPA-ssDNA
A prospective study of quality of life in breast cancer patients undergoing radiation therapy
Benefit of adjuvant radiotherapy after breast‐conserving therapy among elderly women with T1‐T2N0 estrogen receptor‐negative breast cancer